These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 24646480)

  • 1. A snapshot of challenges and solutions in cancer drug development and therapy.
    Phelps MA; Sparreboom A
    Clin Pharmacol Ther; 2014 Apr; 95(4):341-6. PubMed ID: 24646480
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecularly targeted cancer therapy: some lessons from the past decade.
    Huang M; Shen A; Ding J; Geng M
    Trends Pharmacol Sci; 2014 Jan; 35(1):41-50. PubMed ID: 24361003
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [New anticancer drugs: much ado about nothing?].
    Zimmermann S; Betticher D
    Rev Med Suisse; 2014 Apr; 10(425):788, 790-3. PubMed ID: 24791424
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The opportunities and challenges of personalized genome-based molecular therapies for cancer: targets, technologies, and molecular chaperones.
    Workman P
    Cancer Chemother Pharmacol; 2003 Jul; 52 Suppl 1():S45-56. PubMed ID: 12819933
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimizing oncology therapeutics through quantitative translational and clinical pharmacology: challenges and opportunities.
    Venkatakrishnan K; Friberg LE; Ouellet D; Mettetal JT; Stein A; Trocóniz IF; Bruno R; Mehrotra N; Gobburu J; Mould DR
    Clin Pharmacol Ther; 2015 Jan; 97(1):37-54. PubMed ID: 25670382
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Challenges of developing therapeutics that target signal transduction in patients with gynecologic and other malignancies.
    Rowinsky EK
    J Clin Oncol; 2003 May; 21(10 Suppl):175s-186s. PubMed ID: 12743132
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mathematical modeling in cancer drug discovery.
    Wang Z; Deisboeck TS
    Drug Discov Today; 2014 Feb; 19(2):145-50. PubMed ID: 23831857
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nanomedicine for targeted cancer therapy: towards the overcoming of drug resistance.
    Shapira A; Livney YD; Broxterman HJ; Assaraf YG
    Drug Resist Updat; 2011 Jun; 14(3):150-63. PubMed ID: 21330184
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeted cancer therapies: the future of cancer treatment.
    Kumar M; Nagpal R; Hemalatha R; Verma V; Kumar A; Singh S; Marotta F; Jain S; Yadav H
    Acta Biomed; 2012 Dec; 83(3):220-33. PubMed ID: 23762999
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeted cancer therapy: conferring specificity to cytotoxic drugs.
    Chari RV
    Acc Chem Res; 2008 Jan; 41(1):98-107. PubMed ID: 17705444
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The path to oncology drug target validation: an industry perspective.
    Cortés-Cros M; Schmelzle T; Stucke VM; Hofmann F
    Methods Mol Biol; 2013; 986():3-13. PubMed ID: 23436402
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Curtailing the high rate of late-stage attrition of investigational therapeutics against unprecedented targets in patients with lung and other malignancies.
    Rowinsky EK
    Clin Cancer Res; 2004 Jun; 10(12 Pt 2):4220s-4226s. PubMed ID: 15217962
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The convergence of cancer prevention and therapy in early-phase clinical drug development.
    Abbruzzese JL; Lippman SM
    Cancer Cell; 2004 Oct; 6(4):321-6. PubMed ID: 15488755
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel cytotoxic drugs: old challenges, new solutions.
    Ismael GF; Rosa DD; Mano MS; Awada A
    Cancer Treat Rev; 2008 Feb; 34(1):81-91. PubMed ID: 17905518
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Molecular targeted therapy for cancer].
    Sone S; Kuramoto T; Sato S; Mitsuhashi A; Kakiuchi S; Goto H; Tada H; Nishioka Y
    Nihon Rinsho; 2010 Jun; 68(6):997-1006. PubMed ID: 20535947
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics, clinical indications, and resistance mechanisms in molecular targeted therapies in cancer.
    Izar B; Rotow J; Gainor J; Clark J; Chabner B
    Pharmacol Rev; 2013; 65(4):1351-95. PubMed ID: 24092887
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular-targeted therapies: lessons from years of clinical development.
    Rosa DD; Ismael G; Lago LD; Awada A
    Cancer Treat Rev; 2008 Feb; 34(1):61-80. PubMed ID: 17826917
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Understanding resistance to targeted cancer drugs through loss of function genetic screens.
    Berns K; Bernards R
    Drug Resist Updat; 2012 Oct; 15(5-6):268-75. PubMed ID: 23142522
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New targets and challenges in the molecular therapeutics of cancer.
    Eastman A; Perez RP
    Br J Clin Pharmacol; 2006 Jul; 62(1):5-14. PubMed ID: 16842374
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metronomic scheduling of anticancer treatment: the next generation of multitarget therapy?
    André N; Padovani L; Pasquier E
    Future Oncol; 2011 Mar; 7(3):385-94. PubMed ID: 21417902
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.